Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ProMIS Neurosciences ( (PMN) ) has issued an update.
On September 3, 2025, ProMIS Neurosciences announced that the independent Data and Safety Monitoring Board recommended proceeding to the final dose escalation cohort in the Phase 1b clinical trial of PMN310 for Alzheimer’s treatment. This decision follows a review of safety data from the second cohort, which showed no amyloid-related imaging abnormalities, and supports the company’s timeline to deliver interim and top-line results in 2026. The trial aims to enroll 128 patients and assess biomarkers for potential disease-modifying effects, highlighting PMN310’s differentiated strategy of targeting toxic oligomers while avoiding amyloid plaque.
The most recent analyst rating on (PMN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.
Spark’s Take on PMN Stock
According to Spark, TipRanks’ AI Analyst, PMN is a Underperform.
ProMIS Neurosciences faces significant financial hurdles, with no current revenue and ongoing operational losses, leading to a weak overall financial performance. The technical analysis indicates the stock is under pressure, and the valuation reflects challenges with a negative P/E ratio. While recent corporate events show promise in terms of future growth potential, they do not offset the immediate financial challenges. The overall score reflects the need for cautious optimism, as the company must improve its financials and achieve sustainable revenue generation.
To see Spark’s full report on PMN stock, click here.
More about ProMIS Neurosciences
ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing next-generation therapies for Alzheimer’s disease and other neurodegenerative disorders. The company utilizes its proprietary EpiSelect™ platform to discover and develop therapeutic antibodies and vaccines targeting toxic oligomers associated with diseases such as Alzheimer’s, ALS, and Parkinson’s.
Average Trading Volume: 7,139,897
Technical Sentiment Signal: Strong Sell
Current Market Cap: $27.97M
For a thorough assessment of PMN stock, go to TipRanks’ Stock Analysis page.